Details of issuance or disposal
Completion of exercise and monthly exercise status of the 18th Series Stock Acquisition Rights issued through a third-party allotment (with an exercise price adjustment clause)
Shares delivered during the month: 2,460,000 shares (2,460,000 new shares and 0 treasury shares transferred)
The lower thin line represents the existing number of shares to which these shares will be added.
Proceeds raised: ¥1,543,241,500. Estimated net proceeds: Not disclosed
Exercise ratio subject to the exercise restriction, based on 2,460,000 shares delivered during the month against 46,695,300 listed shares as of the payment date for the issuance: 5.27%
The dilution rate shows what proportion the newly issued shares represent of the existing shares. The higher the proportion, the more the value and voting rights per share are diluted.
| Item | Details |
|---|---|
| Type of issuance or disposal | Completion of exercise and monthly exercise status of the 18th Series Stock Acquisition Rights issued through a third-party allotment (with an exercise price adjustment clause) |
| Number of shares to be issued or disposed of | Shares delivered during the month: 2,460,000 shares (2,460,000 new shares and 0 treasury shares transferred) |
| Amount of funds to be raised | Proceeds raised: ¥1,543,241,500. Estimated net proceeds: Not disclosed |
| Intended allottee | EVO FUND (320,000 rights) |
| Dilution Rate | Exercise ratio subject to the exercise restriction, based on 2,460,000 shares delivered during the month against 46,695,300 listed shares as of the payment date for the issuance: 5.27% |
| Total number of issued shares | 76,235,300 shares (as of the end of the month preceding the relevant month) → 78,695,300 shares (as of 19 May 2026) |
| Exercise price | ¥36. Whether an adjustment clause applies and the adjustment floor: Not disclosed |
| Number of Stock Acquisition Rights | Total number issued: 320,000 rights; remaining unexercised: 0 rights |
| Procedures under the Corporate Code of Conduct | The status of compliance with the exercise restriction under Article 434 of the Listing Regulations is provided. The exercise ratio subject to the exercise restriction is 5.27%. |
| Most recent equity financing | 14 April 2025: Issuance of the 18th Series Stock Acquisition Rights, with EVO FUND as the allottee. Proceeds raised: ¥1,543,241,500 |
Items this document does not state (18)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.All of the 18th Series Stock Acquisition Rights issued on 14 April 2025 were exercised on 19 May 2026. This notice provides the monthly exercise status for May 2026 together with the completion of the exercise.